The use of prescription drugs, including syntheticopiates, is increasing in the U.S., with emergency room reports showing a dramatic rise in prescription opiate abuse. As part of an ongoing study, the hair of admitted opiate users was analyzed for hydrocodone and hydromorphone, as wellas codeine, morphine, and 6-acetylmorphine in order to determine if there was any correlationbetweenself-reported frequency of opiate intakeand the concentration of drug detected in hair. The hairswere confirmed using gas chromatography-mass spectrometry following screening by enzymelinked immunosorbent assay(ELISA). Twenty-four hair specimens collectedfrom volunteers showed the presence of hydrocodone (130-15,933 pg/mg); four of those also contained hydromorphone (59-504 pg/mg). Thespecimens were also analyzed for morphine, codeine,and 6-acetylmorphine. Hair specimens from five self-reported codeineusersshowed concentrations of hydrocodone between592 and 15,933 pg/mg. In addition,codeine was presentat concentrations of 575-20,543 pg/mg, but neither morphine nor hydromorphone were present in any of those hair specimens. Though the analysis of some opiates in hair has been previously published, this is the first studywhere the hydrocodone and hydromorphone concentrations have been measured following self-reported opiate intake.
Introduction
Prescription opioids such as Vicodin'", Lortab" (hydrocodone), and Dilaudid'? (hydromorphone) are becoming increasingly abused in the U.S. Data from the 2003 Drug Abuse Warning Network, which collects information on drug-related episodes from hospital emergency departments in metropolitan areas, aswell as from Medical Examiner offices, listed opiates or opioids as present in 20,830 cases ofemergency room (ER) visits because of overmedication. Non-medical use of opioids accounted for 17% ofER visits. Various surveys indicate an increase in the use of prescription opiates, with hydrocodone being among the drugs showing the mostpronounced trends ofincreasing abuse (1) . In a recent study ofprescription drug * Author to whom correspondence should be addressed. E-mail cmoore@immunalysis.com.
abuse in Miami, 36% of ecstasy users also reported hydrocodone use (2) .
Procedures for the detection of these drugs in urine have been published (3, 4) and there are several publications regarding the incorporation ofopiates into hair (5, 6) , including studies employing the analysis of hair to prove heroin intake and/or distinguish heroin use from morphine or codeine ingestion (7, 8) . As far back as 1994, Nakahara et al. (9) described the importance ofthe efficient extraction ofopiates from hair, comparing five extraction methods. Other procedures for the determination ofdrugs used in the treatmentofheroin addiction, such as methadone (10) , l-a-acetylmethadol (11) , and buprenorphine (12) , in hairhave also been reported. However, we found only one publication specifically describing the detection of hydrocodone and hydromorphone, as well as oxymorphone and oxycodone simultaneously in human hairusing gas chromatography-mass spectrometry (GC-MS) (13) . The paper describes the methodology ofanalysis, but has no results from the analysis of samples where drug intake history was available.
Materials and Methods

Subjects
Ourstudy enrolled subjects from the Drug andAlcohol Recovery Team (DART) in Fullerton, Orange County, Southern California andwas approved underImmunalysis Institutional Review Board (IRB # 2004-05-001). Subjects were made aware of the purpose of the study and gave informed consent. Although information on drug use, including time oflast use, frequency of use, ethnicity, age, gender, and hair color were recorded for each subject, names, addresses, or other identifying information were not collected on the interview sheet. Complete anonymity was established during the sample collection and laboratory testing procedures. Each subject provided a hair specimen taken from the vertex portion of the head at the time of interview. The subjects were asked if they took opiates, not specifically heroin, codeine, or other synthetic opiates. None of the subjects reported having a pre-scription for opiates. Hair was transported to the testing facility andstored at room temperature.
Experimental
Hair screening kits were obtained from Immunalysis Corporation (Pomona, CAl. The Opiates Direct ELISA Kit (Catalog # 207-0480) was used for screening the hair specimens and was used according to the manufacturer's instructions. For confirmatory procedures, deuterated morphine-d-, codeine-dj, hydrocodone-dj, hydrornorphone-dj, andfi-acetylrnorphine-dj as internal standards aswell as the corresponding unlabelled drug standards were obtained from Cerilliant (Round Rock, TX). Solid-phase mixed-mode cation exchange-hydrophobic phase extraction columns (CSDAU020, 200 mg) were obtained from United Chemical Technologies Inc. (Bristol, PAl. The derivatizing agent, N,O-bis-trimethylsilyl-trifluoroacetamide (BSTFA) containing 1% trimethylchlorosilane (TMCS), was obtained from Pierce Chemical Co. (Rockford, IL). All solvents were high-performance liquid chromatography grade or better, and all chemicals were American Chemical Society grade.
Screening assay
The Immunalysis Opiates Direct ELISA kit is based upon the competitive binding of enzyme-labeled antigen and unlabeled antigen to antibody in proportion to their concentration in the reaction well. Hair was cut into small segments (3-5 mm), and an aliquotof 10 mgwas weighed. The hair was washed briefly with methanol (2 mL/10 min), the solvent was decanted, and the hair was allowed to dry. To the hairs, 0.025M phosphate buffer (pH 2.7,0.5 mL) was added; the tubes were capped and incubated at 60°C for 2 h. Phosphate buffer (O.5M, pH 9.0, 50 ul.)was added to neutralize the acid environment, and the liquids were transferred to corresponding clean glass tubes. Astandard curve consisting ofa drug-free negative hair specimen, a drug-free hair specimen spiked at 100pg/mg of morphine, and a drug free hair specimen spiked at 400 pglmg of morphine, as well as a cut-off calibrator at 200 pglmg morphine were included in duplicate in every batch. All specimens, calibrators, and controls were diluted 1:5 by adding 400 ul, ofphosphate buffer saline (PBS), with 0.1 % bovine serum albumin (pH 7.0) to 100 ul, of extract. An aliquot ofthe diluted hair extract (20 ul.) was then added to the individual microplate well, and the screening assay was performed according to the manufacturer's instructions. Theassay performance was optimal when 20-60 pg of morphine were placed into the microplate well. A sample size of20ul, ofthe diluted hair extract gave good separation at the screening cut-off concentration of 200 pg of morphine equivalents permilligram ofhair. The assay showed broad spectrum cross reactivity withother opiates, including codeine (200%), hydrocodone (93%), 6-acetylmorphine (83%), hydromorphone (81%), oxycodone (21%), and oxymorphone (20%).
Efficiency of screening extraction
The extraction efficiency of the screening assay was determined. Three hair specimens already confirmed for the pres-ence ofopiates were selected and analyzed according to the described procedure. After the first extract solution was removed, the hairwas rinsed, dried, andre-extracted for 1 h (Extract 2). The solution was removed, anda third extraction was carried out (Extract 3).The extracts were screened as described or, if necessary, further diluted intothe linear range ofthescreening assay.
Confirmatory assay
Specimens showing inhibition lower thanthat ofthe cut-off calibrator (200 pglmg) were considered to be presumptively positive for opiates andwere carried forward to confirmation using GC-MS, operating in electron impact mode.
A separate aliquot of hair was weighed out (10 mg). Low (100 pg/mg), medium (200 pg/rng), and high (500 pglmg) controls were also prepared. The internal standard solution contained deuterated morphine-dj, codeine-dj, acetylmorphine-d, (6-AM), hydromorphone-dj, and hydrocodone-d, in acetonitrile (200 nglmL). The samples were incubated in acetone (1.5 mL) for5 min at roomtemperature to remove gels, sprays, or extraneous cosmetic treatments on the hair, and then the acetone was discarded. Internal standard (50 mL) was added to each calibrator, control, or hair specimen at a concentration of1000 pglmg. Methanol (3 mL) was added, andthe samples were allowed to sonicate (2 hI70°C). The methanol was decanted and evaporated to dryness. To the remaining hair, O.1M hydrochloric acid (1.5 mL) was added, and the tubeswere capped and incubated overnight at 55°C. The acid was decanted into the corresponding dried methanol tube, and O.1M phosphate buffer (pH 6.0; 3 mL) was added. Solidphase mixed mode extraction columns (CleanScreen CSDAU0133) were placed into a vacuum manifold. Each column was conditioned with ethyl acetate (2 mL), methanol (2 mL), and O.1M phosphate buffer (pH 6.0; 2 mL). The samples were allowed to flow through the columns, then the columns were washed with deionized water (1 mL), O.1M hydrochloric acid (1 mL), methanol (1 mL), andethyl acetate (1 mL). The columns were allowed to dry underpressure (15 psi, 5 min). The drugs were finally eluted using freshly prepared ethyl acetate/2% ammonium hydroxide (98:2, 3 mL). Theextracts were evaporated to dryness undernitrogen and reconstituted in ethyl acetate (25 ilL) and BSTFA-l%TMCS (25 ilL). Thetubes were capped andheated at 70°C for20 min.The extracts were transferred to autosampler vials for analysis by GC-MS. Controls andcalibrators were included in each batch as described.
Analytical procedure (GC-MS)
Forconfirmation ofthe presence ofopiates, anAgilent Technologies 6890 GC coupled to a 5975 mass selective detector operating in electron impact mode was used for analysis (GC-MS). The GC column was a DB-5 MS (0.25-mm i.d., 0.25-11m film thickness, 15-m length, J&W Scientific, an Agilent Company), and the injection temperature was 250°C. The injection mode was splitless. The oven was programmed from 100°C for 0.5 min, ramped at 40°C/min to 230°C, then ramped at 5°C/min to 250°C. The transfer line was held at 280°C, the MS source was 230°C, andthe quadropole at 150°C. The ions monitored were as follows: deuterated codeine and hydrocodone m/z 374 (237); unlabelled codeine and hydrocodone m/z371, (234, 196) ; deuterated morphine and hydromorphone 
Efficiency of confirmatory extraction
The extraction efficiency of the method was established. Six hair specimens containing high concentrations of opiates, relative to the 200 pg/mg screening cut-off, were selected andanalyzed according to the extraction protocol. The remaining hair was dried and extracted again; the hair remaining from that was subjected to a third extraction procedure. The extracts were confirmed using the GC-MS procedure described.
Results and Discussion
Method validation
GC-MS. The precision ofthe assay was determined by analyzing hair specimens containing codeine, morphine, and 6-acetylmorphine at concentrations of50, 100,200,500, and 1000 pg/mg. The interday precision ofthe assay at 200 pglmg for codeine, morphine, and 6-acetylmorphine was 2.20%, 2.97%, and2.27%, respectively, (n = 6). The intraday precision was 2.37%, 2.78%, and 0.53% for codeine, morphine, and 6-AM, respectively, (n = 5). The limit of quantitation of the system was 50pglmg for all analytes; thecorrelation coefficient for all calibration curves was greater than r 2 = 0.99, and the upper limit oflinearity was 1000 pg/mg, Specimens exceeding the upper limit were either re-extracted using less sample volume or diluted so the analytical value lay within the calibration curve parameters.
Extraction efficiency. The extraction efficiency ofboth the screening procedure andthe confirmatory extraction methods were determined. The screening method was efficient, with an average extraction recovery of79.2% ofmorphine equivalents in the first hourofincubation. After the second hour, the mean recovery was 91.7% with a coefficient of variation of 6.3% (n =3). The confirmatory procedure was also extremely efficient with recoveries for all four opiates over 93% (n =6).
The results areshown in Tables I-III .
Specimens
Overall, 24hairspecimens tested positively for hydrocodone or hydromorphone.
Hydrocodone. Hydrocodone was present in all24synthetic opiate-positive samples. Eight ofthe subjects did not admit to opiate use ofany kind. Five subjects reported specifically to the Journal of Analytical Toxicology, Vol. 30, July/August 2006 ingestion ofcodeine, andallprovided hairsamples that tested positively for hydrocodone and codeine (it should be noted that oneofthe subjects admitted hydrocodone intake in addition to codeine). Three individuals reported hydrocodone use in addition to heroin or codeine intake, and all were positive for hydrocodone in the hair.
The self-reported drug intake of the subjects is shown in Table IV along with theanalytical results. Hydrocodone was detected in all hair samples following admitted codeine intake, but, notably, morphine was not detected in measurable concentrations.
Hydromorphone. Foursamples contained hydromorphone above the limit of quantitation (Table III) . Two were from 
15,933
, Abbreviations; 6-AM, 6-acetylmorphine; HYC, hydrocodone; HYM, hydromorphone; MTD, methadone;and NA, no admission of opiate intake. I(JGrey -B/tlck eI Brown I present both asa result ofcodeine metabolism and/or ingestion ofhydrocodone itself. There was no apparent correlation between the concentrationofthe opiates in hair andthe amount ofcodeine reported by the subjects. The same was true following heroin use: there appeared to be no correlation with codeine, morphine, or 6-acetylmorphine levels in hair, although nine out of 10 hair specimens from these subjects were positive for 6-acetylmorphine (Figure 1) . The only samplethat did not show the presence offi-acetylmorphinewas from an individual admitting to heroin use only once a month. The only two samples from heroin users, which were positive for hydromorphone, had correspondingly high levels ofmorphine; in fact, they were the highest concentrations ofmorphine detected in thisspecimen pool. The ratio ofhydromorphone to morphine in both cases was 0.03. This observation supports the possibility that hydromorphone is a minor metabolite of morphine, which has been reported (21). 
Limitation of the study
The main limitation toourstudy isthe reliance upon self-reported drug intake. When subjects take tablets (as in the case ofhydrocodone andcodeine) it is more likely that the amount ingested is known, compared with heroin use, where the potency andfrequency ofuse may besuspect. Studies conducted in the 1980s concluded that individuals provide valid information on illegal drug use when theconditions ofinterview are appropriate. However, it has been shown that clients report heroin use while in treatment programs, butat the post-treatment follow up, heroin use issignificantly under-reported (22) . Colon et al. (23) , based on hairanalysis, reported a sensitivity ofself-reports for heroin use of78.6%. More recently, Fishbain et al. (24) noted that theself-reporting ofcannabis and cocaine use in chronic pain patients was not well supported by urine toxicology, with sensitivity results indicating that a significant percentage (8.8%) of subjects who claimed to be drug-users were not actually taking the drug or were not taking it correctly. Apparently, the reliability of self-reported drug use depends largely on the situation ofthe subjects. In certain circumstances, where adverse results are not associated with admission, reliable self-reporting of opiate use has been shown (25) . subjects admitting frequent heroin use; two were from subjects not admitting any opiate intake. As for the two admitted heroin users, their hair specimens also contained codeine (1958 and 5743 pg/rng), hydrocodone (202 and 161 pg/rng}, morphine (9 160 and 15,206 pg/mg), and 6-acetylmorphine (9925 and 7623 pg/mg), The morphine levels in thesetwo sampleswere the highest from anyofthe positive specimens.
There areseveral reports ofextraction andanalytical procedures for the determination of opiates in hair (14) , but none focus on hydrocodone or hydromorphone following self-reported intake. Research groups have administered known amounts ofcodeine tosubjects andsubsequently measured the opiate content of hair. Morphinewas not detected in hair following multiple oral doses ofcodeine (15, 16) . Scheidweiler et al. (17) reported codeine concentrations in hair from subjects taking low doses ofcodeine on alternate days anddid not consider the detection of morphine in hair specimens following codeine administration to be significant because concentrations did not exceed 83pglmgin any subject (n =10). None of these studies included hydrocodone in their analytical hair assay. However, in rat hair, codeine, morphine, and morphine glucuronide were incorporated in hair in a dose-related manner following codeine administration (18) , andin onefurther publication regarding human subjects, the presence of morphine at a concentration of400 pglmg following lowdoses ofcodeine administration (3 x 60 mg perweek) was reported (19) . This was the only publication found that detected measurable morphine in hair following codeine intake, and the morphine was only present in one sample from one subject. Though our study is consistent with the majority of reported data, in that morphine is generally not detected above 20 pglmg in hair specimens taken from admitted codeine users, we arethe first to report the presence ofhydrocodone in all the samples. Oyler et al. (20) reported the identification of hydrocodone in human urine following controlled codeine administration, andour results appear to support theobservation that hydrocodone isa metabolite ofcodeine. However, it should be noted that the presence of hydrocodone could have been
Correlation
There appeared to be no correlation between amount of drug ingested and the concentration of any drug or drug metabolite detected in hair. Such a correlation has been reported for codeine, when the codeine levels arenormalized to the melanin (phaeomelanin and eumelanin) content of the hair. Unfortunately, the amount ofhairneeded to carry out the determination of total melanin, eumelanin, screening, and confirmation of each hair was impractical in our study. According to the method ofKronstrand et al. (26) ,50 mgofhair was necessary for total melanin determination and30 mgfor eumelanin. Our study required 10 mgfor screening and 20mg for confirmation, requiring a total of 110 mgofhair per subject, assuming no repeats were necessary.
Because melanin is predominantly responsible for hair coloration, we assessed theaverage opiate concentration based on thehair color ofsubjects in thestudy (Figure 2 ). There was only one red-haired subject and only one blonde subject positive for morphine and 6-acetylmorphine; thus, these haircolors were notincluded intheaverage values reported. Overall, grey-haired subjects had thehighest average concentration ofcodeine (5069 pglmg) and hydrocodone, (6337 pg/mg; x = 54 years) in hair. The mean age ofblack-haired subjects was 48.8 years, and they showed the highest average concentration ofmorphine (6144 pg/mg) and 6-acetylmorphine (2931 pg/rng). However, the number ofsubjects in each haircolor class was limited; therefore, nodefinitive conclusion can bedrawn regarding haircolor and opiate concentration. The age ofthesubjects ranged from 26 to 62 years, but only two were younger than42 years.
Conclusions
In summary, hydrocodone can be readily detected in hair specimens. Following admitted codeine use, all hair samples contained hydrocodone, and none showed thepresence ofmorphine, 6-acetylmorphine, or hydromorphone. In two of the cases, the hydrocodone concentration was significantly higher thanthe codeine. There appeared tobenocorrelation between self-reported opiate intake and concentration in hair.
